ARTICLE | Clinical News

PRM-151: Phase II ongoing

January 13, 2014 8:00 AM UTC

Promedior completed enrollment of 25 patients with primary MF and post polycythemia vera/essential thrombocythemia MF (PPV-MF/PET-MF) in the first stage of a 2-stage, open-label, North American Phase II trial evaluating 10 mg/kg IV PRM-151. Patients will receive weekly or monthly PRM-151 with or without ruxolitinib in the first stage, which the company expects to complete this year. Up to an additional 80 patients will be enrolled in the second stage. ...